Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: A retrospective study with implications for trial design

Neuromuscular Disorders

Volumn 25, Issue 3, 2015, Pages 238-246

  Youssof, Sarah ^a   Schrader, Ronald ^a   Bear, David ^a   Morrison, Leslie ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Mobility impairment; Natural history; Oculopharyngeal muscular dystrophy; Outcome measures; Time to event analysis

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPHAGIA; EYE SURGERY; FEMALE; HIP FLEXION WEAKNESS; HUMAN; IMMOBILITY; LEG MOVEMENT; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; ONSET AGE; PRIORITY JOURNAL; PTOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; WALKING AID; AGE; BLEPHAROPTOSIS; COMORBIDITY; DEGLUTITION DISORDERS; DISEASE COURSE; GENETICS; HIP; MIDDLE AGED; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; PATHOPHYSIOLOGY; PREVALENCE; SELF HELP DEVICE; SEVERITY OF ILLNESS INDEX; SHOULDER; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLEPHAROPTOSIS; COMORBIDITY; DEGLUTITION DISORDERS; DISEASE PROGRESSION; FEMALE; HIP; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; NEW MEXICO; PREVALENCE; RETROSPECTIVE STUDIES; SELF-HELP DEVICES; SEVERITY OF ILLNESS INDEX; SHOULDER;

EID: 84924288881     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.11.010     Document Type: Article

References (42)

1. Victor M., Hayes R., Adams R.D. Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med 1962, 267:1267-1272.
2. Brais B., Tome F. Oculopharyngeal muscular dystrophy. Myology 2004, 1147-1162. McGraw-Hill, New York. A.G. Engel, C. Franzini-Armstrong (Eds.).
3. Brais B., Bouchard J.P., Xie Y.G., et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998, 18:164-167.
4. Raz V., Butler-Browne G., van Engelen B., Brais B. 191st ENMC International Workshop: recent advances in oculopharyngeal muscular dystrophy research: from bench to bedside 8-10 June 2012, Naarden, The Netherlands. Neuromuscul Disord 2013, 23:516-523.
5. Becher M.W., Morrison L., Davis L.E., et al. Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 2001, 286:2437-2440.
6. Barbeau A. The syndrome of hereditary late onset ptosis and dysphagia in French-Canada. Symposium uber progressive Muskeldystrophie 1966, 102-109. Springer-Verlag, Berlin. E. Kuhn (Ed.).
7. Blumen S.C., Nisipeanu P., Sadeh M., Asherov A., Tome F.M., Korczyn A.D. Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. Neuromuscul Disord 1993, 3:575-577.
8. Taylor E.W. Progressive vagus-glossopharyngeal paralysis with ptosis: a contribution to the group of family diseases. J Nerve Ment Dis 1915, 42:129-139.
9. Mendell J.R., Csimma C., McDonald C.M., et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve 2007, 35:8-16.
10. Allen R.C., Jaramillo J., Black R., et al. Clinical characterization and blepharoptosis surgery outcomes in Hispanic New Mexicans with oculopharyngeal muscular dystrophy. Ophthal Plast Reconstr Surg 2009, 25:103-108.
11. Coiffier L., Perie S., Laforet P., Eymard B., St Guily J.L. Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy. Otolaryngol Head Neck Surg 2006, 135:218-222.
12. Muller T., Schroder R., Zierz S. GCG repeats and phenotype in oculopharyngeal muscular dystrophy. Muscle Nerve 2001, 24:120-122.
13. Van Der Sluijs B.M., Hoefsloot L.H., Padberg G.W., Van Der Maarel S.M., Van Engelen B.G. Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. J Neurol 2003, 250:1307-1312.
14. Rivera D., Mejia-Lopez H., Pompa-Mera E.N., et al. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects. Br J Ophthalmol 2008, 92:998-1002.
15. Tondo M., Gamez J., Gutierrez-Rivas E., Medel-Jimenez R., Martorell L. Genotype and phenotype study of 34 Spanish patients diagnosed with oculopharyngeal muscular dystrophy. J Neurol 2012, 259(8):1546-1552.
16. Witting N., Mensah A., Kober L., et al. Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. Acta Neurol Scand 2014, 130(2):125-130.
17. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.
18. U.S.Census Bureau Census interactive population search accessed 13.03.14. http://www.census.gov/2010census/popmap/ipmtext.php?fl=35.
19. Medici M., Pizzarossa C., Skuk D., Yorio D., Emmanuelli G., Mesa R. Oculopharyngeal muscular dystrophy in Uruguay. Neuromuscul Disord 1997, 7(Suppl. 1):S50-S52.
20. Bouchard J.P., Brais B., Brunet D., Gould P.V., Rouleau G.A. Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 1997, 7(Suppl. 1):S22-S29.
21. Groll D.L., To T., Bombardier C., Wright J.G. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol 2005, 58:595-602.
22. SAS Institute Inc SAS/STAT® 9.3 user's guide 2011, 3765-3874. SAS Institute Inc., Cary, NC.
23. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data 2002, 1-56. John Wiley & Sons, New Jersey. 2nd ed.
24. R Core Team R: a language and environment for statistical computing 2014, R Foundation for Statistical Computing, Vienna, Austria, accessed 23.05.14. http://www.R-project.org/.
25. Fardeau M., Tome F.M. Oculopharyngeal muscular dystrophy in France. Neuromuscul Disord 1997, 7(Suppl. 1):S30-S33.
26. Lesko L.J., Atkinson A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001, 41:347-366.
27. Cedarbaum J.M., Stambler N., Malta E., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999, 169:13-21.
28. Jackson C.E., Barohn R.J., Gronseth G., Pandya S., Herbelin L. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008, 37:473-476.
29. Blumen S.C., Nisipeanu P., Sadeh M., et al. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord 1997, 7(Suppl. 1):S38-S40.
30. Brunet G., Tome F.M., Samson F., Robert J.M., Fardeau M. Oculopharyngeal muscular dystrophy. A census of French families and genealogic study. Rev Neurol (Paris) 1990, 146:425-429. in French.
31. Hardiman O., Halperin J.J., Farrell M.A., Shapiro B.E., Wray S.H., Brown R.H. Neuropathic findings in oculopharyngeal muscular dystrophy. A report of seven cases and a review of the literature. Arch Neurol 1993, 50:481-488.
32. Finsterer J. Involvement of the peripheral nerves in oculopharyngeal muscular dystrophy. Clin Neurophysiol 2010, 121:803-804.
33. Blumen S.C., Bouchard J.P., Brais B., et al. Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes. Neurology 2009, 73:596-601.
34. Dubbioso R., Moretta P., Manganelli F., et al. Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. J Neurol 2012, 259(5):833-837.
35. Martyn C.N., Hughes R.A. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997, 62:310-318.
36. Petersen R.C., Roberts R.O., Knopman D.S., et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 2010, 75:889-897.
37. Jenal M., Elkon R., Loayza-Puch F., et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 2012, 149:538-553.
38. Mayr C., Bartel D.P. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009, 138:673-684.
39. Centers for Disease Control and Prevention, U.S.Department of Health and Human Services Summary health statistics for U.S. adults: National Health Interview Survey p. 26, accessed 15.05.14. http://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf.
40. Mirabella M., Silvestri G., de Rosa G., et al. GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy. Neurology 2000, 54:608-614.
41. Barbezier N., Chartier A., Bidet Y., et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol Med 2011, 3:35-49.
42. Abu-Baker A., Laganiere J., Gaudet R., et al. Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/beta-catenin pathway. Cell Death Dis 2013, 4:e821.